Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)
China flag China · Delayed Price · Currency is CNY
79.52
-3.66 (-4.40%)
Nov 17, 2026, 3:00 PM CST

SHA:688266 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
568.74-162.95-137.83-278.58-457.33-451
Depreciation & Amortization
49.6349.6355.654.0466.3750.77
Other Amortization
5.975.975.736.364.442.62
Loss (Gain) From Sale of Assets
-0-0---0.02-
Asset Writedown & Restructuring Costs
---0.280.110.01
Loss (Gain) From Sale of Investments
-1.2-1.2-6.86-14.68-6.58-12.8
Provision & Write-off of Bad Debts
0.420.422.220.641.43.28
Other Operating Activities
89.49-28.75-33.488.77-15.57-4.53
Change in Accounts Receivable
-24.4-24.4-58.17-38.35-17.41-84.19
Change in Inventory
9.599.59-72.01-11.87-47.07-28.77
Change in Accounts Payable
123.55123.55285.2778.4967.1438.99
Change in Other Net Operating Assets
3.343.341.62-34.1137.0734.62
Operating Cash Flow
821.13-28.7838.2-232.75-370.34-454.62
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-121.53-181.47-95.69-62.6-88.62-70.74
Sale of Property, Plant & Equipment
---000
Investment in Securities
167.45116.12-1,764115-182.1380.01
Other Investing Activities
129.029.7114.8612.446.6617.39
Investing Cash Flow
174.94-55.63-1,84564.84-264.06326.66

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-1,1271,288983.8561171.4
Long-Term Debt Repaid
--1,022-1,150-644.19-242.77-64.91
Lease Payments
-12.07-12.07-15.05-14.19-10.17-7.46
Net Debt Issued (Repaid)
-570.43104.92138.43339.61318.23106.49
Issuance of Common Stock
--0.341,192--
Common Dividends Paid
-21.28-26.09-24.56-21.17-11.22-4.14
Other Financing Activities
-21.24-86.32-165.52-1.45-24.23-8.36
Financing Cash Flow
-612.96-7.5-51.321,509282.7993.99

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-7.27-0.69-2.30.224.07-1.44
Net Cash Flow
375.84-92.61-1,8611,342-347.54-35.41

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
699.61-210.25-57.49-295.35-458.97-525.36
Free Cash Flow Growth
------
Free Cash Flow Margin
39.90%-25.94%-10.79%-76.43%-151.82%-275.98%
Free Cash Flow Per Share
2.68-0.80-0.22-1.16-1.92-2.19
Levered Free Cash Flow
281.87-337.26-165.35-325.09-297.1-353.47
Unlevered Free Cash Flow
295.68-322.14-147.3-310.99-289.58-350.71
Free Cash Flow After Leases
687.54-222.31-72.53-309.54-469.13-532.82

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
93.5780.5651.2415.67-17.55-30.33
Change in Working Capital
108.09108.09152.83-9.5836.84-42.98